Navigation Links
Medical Device Industry Executive Joins OrthoAccel Technologies, Inc. Board of Directors
Date:10/14/2010

HOUSTON, Oct. 14 /PRNewswire/ -- OrthoAccel Technologies, Inc., developers of the AcceleDent System, an acceleration device to enhance orthodontics, announced this week that it has engaged Todd Cooper as a Director on its Corporate Board.  Mr. Cooper's directorship will involve oversight and corporate governance of the Company's business strategy, with a focus on market growth.

(Logo:  http://photos.prnewswire.com/prnh/20091029/DA01250LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20091029/DA01250LOGO)

AcceleDent is a simple, removable dental device that an orthodontic patient wears in the mouth for 20 minutes daily to accelerate orthodontic tooth movement.  A Phase I clinical trial in 2008 in Houston, Texas demonstrated the safety of the device.  The first completed AcceleDent case in private practice was documented earlier this month in the United Kingdom.

Mr. Cooper's background is particularly relevant to OrthoAccel's development of the AcceleDent brand.  His extensive experience includes general management, sale, marketing and product development on a global basis.  While at Discus, a market leader across numerous dental aesthetic  product categories, his leadership resulted in aggressive revenue growth and increasing profitability.  Most recently, Mr. Cooper managed the $400 million medical surgical business at Henry Schein, a $6.5 billion life sciences company.

Michael Lowe, CEO of OrthoAccel, commented, "We knew immediately that Todd's insight could help us shape our strategic direction.  There are many important parallels between OrthoAccel and the businesses that he has successfully managed in the past."  Mr. Cooper remarked, "AcceleDent can revolutionize the orthodontic market space and has huge market potential globally, much like Discus' whitening products did in the aesthetic space. AcceleDent addresses the fundamental desire by patients to shorten the time they need to use orthodontic appliances. I look forward to actively working with the Board and Management Team to build a strong global business."

Last month, OrthoAccel attended the British Orthodontic Conference, where it hosted a reception to feature the learnings from a select group of orthodontic specialist doctors who had been using the product for about a year.  Later this month, a lecture series will be held in Australia, where the device is also available, to further generate awareness around the AcceleDent science and favorable clinical outcomes.  This event is being coordinated in conjunction with AB Orthodontics, the exclusive distributor of AcceleDent in Australia.

OrthoAccel is nearing conclusion of another US clinical trial at the UT Health Science Center in San Antonio with an anticipated completion date in 2010.

About OrthoAccel Technologies, Inc.

Based in Houston, Texas, OrthoAccel Technologies, Inc. is a privately owned medical device company currently engaged in the development, manufacturing, and marketing of products to enhance dental care and orthodontic treatment.

About the AcceleDent System

AcceleDent represents the first clinical approach to safely accelerate orthodontic tooth movement via modulating biology.  The device has been studied clinically and applies gentle pulsing forces in combination with standard orthodontics to move teeth faster through accelerated bone remodeling.  Importantly, the device works complementary with all existing orthodontic technologies.  AcceleDent is neither FDA cleared nor FDA approved; it is currently investigational only in the United States.  More information can be found at www.acceledent.com or requested via info@orthoaccel.com


'/>"/>
SOURCE OrthoAccel Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. You May Have a Thyroid Problem and Not Know It - Particularly If Youre Over 60, Says a New Harvard Medical School Report
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. Globus Medical Raises $110 Million in Series E Financing Round
5. Quark Pharmaceuticals Appoints New Chief Medical Officer
6. Boston University Biomedical Engineers Find Chink in Bacterias Armor
7. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
8. Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study
9. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
10. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
11. Rockwell Medical Technologies, Inc. Begins Dosing Patients for SFP Phase IIb Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):